Survival Extension

In a presentation at the European Society for Medical Oncology, researchers reported that Roche's Perjeta (pertuzumab) could extend patients' lives, the New York Times reports.

According to lead researcher Sandra Swain from the MedStar Washington Hospital Center, patients who received the drug, which treats metastatic breast cancer, had a median survival time 16 months longer than those in the control group.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genomic analysis of modern and ancient maize reveals a complicated domestication history, according to Reuters.

In PLOS this week: MYRF variant linked to congenital diaphragmatic hernia, analysis of the "dragon's blood" red resin produced by traditional medicine plants, and more.

CNBC reports that half of academic researchers leave after about five years.

Researchers have used genetic analysis to confirm a new type of salamander, the New York Times reports.